Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MD
stocks logo

MD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
486.23M
-3.21%
0.538
+5.5%
473.79M
+3.37%
0.385
+16.53%
485.63M
+3.58%
0.568
+7.2%
Estimates Revision
The market is revising Upward the revenue expectations for Pediatrix Medical Group, Inc. (MD) for FY2025, with the revenue forecasts being adjusted by 1.17% over the past three months. During the same period, the stock price has changed by 30.58%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.17%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+16.58%
In Past 3 Month
Stock Price
Go Up
up Image
+30.58%
In Past 3 Month
Wall Street analysts forecast MD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MD is 21.33 USD with a low forecast of 17.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast MD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MD is 21.33 USD with a low forecast of 17.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 22.290
sliders
Low
17.00
Averages
21.33
High
24.00
Current: 22.290
sliders
Low
17.00
Averages
21.33
High
24.00
Truist
David MacDonald
Hold
maintain
$17 -> $24
2025-11-10
Reason
Truist
David MacDonald
Price Target
$17 -> $24
2025-11-10
maintain
Hold
Reason
Truist analyst David MacDonald raised the firm's price target on Pediatrix Medical to $24 from $17 and keeps a Hold rating on the shares. The firm is updating its model to reflect the company's Q3 earnings beat and guidance raise, the analyst tells investors in a research note.
UBS
Neutral
maintain
$23
2025-11-05
Reason
UBS
Price Target
$23
2025-11-05
maintain
Neutral
Reason
UBS raised the firm's price target on Pediatrix Medical to $23 from $16.50 and keeps a Neutral rating on the shares. Pricing growth drove a strong Q3, and UBS expects stable hospital administrative fees in 2026, the analyst tells investors in a research note.
Truist
David MacDonald
Hold
maintain
$16 -> $17
2025-10-14
Reason
Truist
David MacDonald
Price Target
$16 -> $17
2025-10-14
maintain
Hold
Reason
Truist analyst David MacDonald raised the firm's price target on Pediatrix Medical to $17 from $16 and keeps a Hold rating on the shares as part of a broader research note previewing Q3 results in Healthcare Service. The firm is "broadly bullish" on the industry as it expects ongoing strength in core demand drivers and continues to like the long-term positioning of covered names within their sector verticals, coupled with improved visibility around the regulatory environment, the analyst tells investors in a research note. Strong free cash flows and attractive financial flexibility across the bulk of the sector underpins the ongoing growth investment, Truist notes, adding that it sees a "brisk opportunity" to deploy capital to further augment core growth and drive M&A.
UBS
AJ Rice
Neutral
maintain
$16
2025-08-14
Reason
UBS
AJ Rice
Price Target
$16
2025-08-14
maintain
Neutral
Reason
UBS analyst AJ Rice raised the firm's price target on Pediatrix Medical to $16.50 from $16 and keeps a Neutral rating on the shares.
UBS
AJ Rice
Neutral
downgrade
$16
2025-05-12
Reason
UBS
AJ Rice
Price Target
$16
2025-05-12
downgrade
Neutral
Reason
UBS analyst AJ Rice lowered the firm's price target on Pediatrix Medical to $16 from $18.50 and keeps a Neutral rating on the shares. 2025 is starting out strong for Pediatrix, and capital deployment remains a focus, the analyst tells investors in a research note.
Truist Securities
David Macdonald
Hold
Maintains
$18 → $16
2025-04-11
Reason
Truist Securities
David Macdonald
Price Target
$18 → $16
2025-04-11
Maintains
Hold
Reason
Truist analyst David MacDonald lowered the firm's price target on Pediatrix Medical to $16 from $18 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services and adjusting the firm's models. The sector looks relatively well positioned in a fluid environment given the scaled, largely domestic, attractive free cash flow generating, defensive nature of the group, and while regulatory developments remain an area of focus, the Medicare Advantage final rule reinforced the firm's expectation of a better environment, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Pediatrix Medical Group Inc (MD.N) is 10.34, compared to its 5-year average forward P/E of 11.08. For a more detailed relative valuation and DCF analysis to assess Pediatrix Medical Group Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
11.08
Current PE
10.34
Overvalued PE
15.22
Undervalued PE
6.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
8.72
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
11.17
Undervalued EV/EBITDA
6.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.76
Current PS
0.00
Overvalued PS
1.08
Undervalued PS
0.44
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

MD News & Events

Events Timeline

(ET)
2025-11-03
06:06:06
Pediatrix Medical increases FY25 adjusted EBITDA forecast to a range of $270M-$290M.
select
2025-11-03
06:05:04
Pediatrix Medical announces Q3 adjusted EPS of 67 cents, surpassing consensus estimate of 47 cents.
select
2025-08-18 (ET)
2025-08-18
16:31:32
Pediatrix Medical unveils $250 million stock buyback initiative
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.0
11-24NASDAQ.COM
Top Value Stocks to Consider Purchasing on November 24

  • Top Stock Picks: Three stocks with strong value characteristics and a Zacks Rank #1 are highlighted: John B. Sanfilippo & Son, Inc. (JBSS), Grupo Cibest S.A. (CIB), and Pediatrix Medical Group, Inc. (MD), all showing significant earnings estimate increases over the past 60 days.

  • Valuation Metrics: JBSS has a P/E ratio of 11.84, CIB has a P/E of 7.81, and MD has a P/E of 11.19, all indicating favorable valuations compared to their respective industry or market averages.

  • Investment Opportunities: The article suggests that these stocks are under the radar of Wall Street, presenting a potential opportunity for investors to capitalize on their growth, with previous recommendations yielding substantial returns.

  • Further Recommendations: Zacks Investment Research offers additional stock recommendations, emphasizing the potential for significant gains in the coming months, with a free report available for interested investors.

[object Object]
Preview
4.0
11-24NASDAQ.COM
Top Strong Buy Stocks for November 24: SHIP, MD, and Others

  • Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including Amer Sports, Intuitive Surgical, Pediatrix Medical Group, Seanergy Maritime Holdings, and Grupo Cibest, all showing significant increases in earnings estimates over the past 60 days.

  • Earnings Growth: The companies listed have seen varying increases in their Zacks Consensus Estimates for current year earnings, with Seanergy Maritime Holdings leading at 66.7%, followed by Pediatrix Medical Group at 15.7%.

  • Investment Opportunities: The article highlights that these stocks are considered under the radar by Wall Street, presenting a potential opportunity for investors to capitalize on significant growth, with previous recommendations yielding returns of +171%, +209%, and +232%.

  • Access to Recommendations: Zacks Investment Research offers a free report titled "7 Best Stocks for the Next 30 Days," which includes detailed analyses of the featured stocks and their potential for future gains.

[object Object]
Preview
9.5
11-16Yahoo Finance
Pediatrix Medical Group (MD) Reports Increased Q3 Earnings Amid Sales Decline—Is Emphasis Shifting to Profitability?

  • Earnings Performance: Pediatrix Medical Group reported a net income of $71.71 million and diluted earnings per share of $0.84 for Q3 2025, despite a sales decline to $492.88 million, indicating improved profitability amid revenue challenges.

  • Investment Outlook: The company's ability to maintain profitability in specialized pediatric care is crucial for its medium-term investment outlook, with a projected revenue of $2.1 billion and earnings of $145.1 million by 2028.

  • Share Repurchase Program: A $250 million share repurchase program launched in August 2025 reflects the company's confidence in capital allocation, providing flexibility to enhance shareholder value during a transitional phase.

  • Valuation Concerns: Current fair value estimates for Pediatrix Medical Group's stock vary significantly, with a potential downside of 14% from its current price, highlighting risks associated with revenue contraction and restructuring efforts.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pediatrix Medical Group Inc (MD) stock price today?

The current price of MD is 22.29 USD — it has decreased -4.29 % in the last trading day.

arrow icon

What is Pediatrix Medical Group Inc (MD)'s business?

Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.

arrow icon

What is the price predicton of MD Stock?

Wall Street analysts forecast MD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MD is 21.33 USD with a low forecast of 17.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pediatrix Medical Group Inc (MD)'s revenue for the last quarter?

Pediatrix Medical Group Inc revenue for the last quarter amounts to 492.88M USD, decreased -3.58 % YoY.

arrow icon

What is Pediatrix Medical Group Inc (MD)'s earnings per share (EPS) for the last quarter?

Pediatrix Medical Group Inc. EPS for the last quarter amounts to 0.84 USD, increased 265.22 % YoY.

arrow icon

What changes have occurred in the market's expectations for Pediatrix Medical Group Inc (MD)'s fundamentals?

The market is revising Upward the revenue expectations for Pediatrix Medical Group, Inc. (MD) for FY2025, with the revenue forecasts being adjusted by 1.17% over the past three months. During the same period, the stock price has changed by 30.58%.
arrow icon

How many employees does Pediatrix Medical Group Inc (MD). have?

Pediatrix Medical Group Inc (MD) has 2150 emplpoyees as of December 05 2025.

arrow icon

What is Pediatrix Medical Group Inc (MD) market cap?

Today MD has the market capitalization of 1.91B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free